Atossa Genetics, Inc. to Present at Upcoming Investor Conferences in September 2016

SEATTLE, WA--(Marketwired - Sep 12, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS) today announced it will be a featured presenter at the Rodman & Renshaw 18th Annual Global Investment Conference, being held September 11-13, 2016 at the Lotte New York Palace Hotel, in NY, NY. The Company will also be a featured presenter at the Aegis Capital Growth Conference, being held September 20-22, 2016 at the Encore at Wynn in Las Vegas, NV.

Kyle Guse, CFO and General Counsel will discuss the Company's business model and growth strategies at the Rodman & Renshaw conference on Monday, September 12, 2016 at 5:05-5:30 PM EDT, in Louis Room (4th Floor). Mr. Guse will present at the Aegis Capital Growth Conference on Thursday, September 22, 2016 at 9:00 AM PDT in Room 3. Mr. Guse will be available for one-on-one investor meetings at both events.

For more information on the Rodman & Renshaw 18th Annual Global Investment Conference please visit: http://www.hcwainwright.com/conference

For more information on the Aegis Capital Growth Conference please visit: http://www.meetmax.com/sched/event_37061/~public/conference_home.html?event_id=37061

About Atossa Genetics

Atossa Genetics, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies and timing of publication of those results, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others including with respect to Fulvestrant, such as patent rights, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.